Real-world off-label use of icatibant for acute management of non-hereditary angioedema.

We retrospectively examined the indications and efficacy of off-label use of the bradykinin B2 receptor antagonist icatibant. The clinical heterogeneity, variability of response to icatibant and lack of efficacy of adrenaline described in this audit highlights both the need for biomarkers that can rapidly distinguish between histaminergic and non-histaminergic angioedema, and for guidelines to improve the utility of icatibant in the non-hereditary angioedema setting. © 2021 Royal Australasian College of Physicians.

Citation

Thanh-Thao Adriana Le, William Smith, Pravin Hissaria. Real-world off-label use of icatibant for acute management of non-hereditary angioedema. Internal medicine journal. 2021 Mar;51(3):419-423

Mesh Tags

Substances

PMID: 33738947

search → result